Avalon Healthcare Solutions
Member Level: PlatinumVendor Overview
Description of Services: Avalon Healthcare Solutions is the leader in Laboratory Benefit Management.
Avalon is a healthcare information technology and specialty benefit management company focused on laboratory testing. Avalon provides a comprehensive program managing all outpatient laboratory services across all providers, including independent, physician office and hospital-based labs. Using an independent Clinical Advisory Board (CAB), Avalon has developed a suite of science-based lab policies addressing all lab testing categories. These policies are administered through proprietary, automated technology to remove inappropriate utilization and typically saving health plans and TPAs 10% to 18% on outpatient lab spend.
Primary Service: Enterprise Data
Secondary Service: Administrative Systems
Alliance members, log in to view this company's complete profile.
3405 W. Dr. Martin Luther King Jr. Blvd.
Suite 200
Tampa, FL 33607
813-751-3800
http://avalonhcs.com
Documents
eBook: The Benefits of Improved Genetic Testing Management: Insights from Chapter 3
The rapid growth of genetic tests has surpassed the ability of plans to ensure their quality and applicability, often lacking regulatory oversight. This chapter explores how improved genetic test management benefits all stakeholders and introduces an innovative approach to validate tests, optimize ordering, enhance reimbursement accuracy, and integrate results into patient care.
Article: Avalon's Washington D.C. Policy Update 06/30
Avalon's final June Policy update dives into recent developments in healthcare policy and innovation, highlighting legislative efforts to expand Medicare coverage for multi-cancer blood tests and regulatory updates impacting laboratory-developed tests. It also covers significant industry news, including legal disputes in diagnostics and partnerships leveraging AI for personalized cancer screening plans.
Report: Avalon's Monthly Insights
This year's report explores market trends in laboratory diagnostics, the FDA LDT Final Rule, and the regulatory landscape affecting genetic and routine testing. It highlights the rise of genetic testing and biomarkers in disease prediction and details how Avalon’s programs address waste, pricing, and spending concerns.
Avalon's Washington D.C. Policy Update June 2024
Avalon Healthcare Solutions' June 16, 2024, update highlights key developments in lab testing, federal healthcare activities, and payer-provider dynamics. Notably, U.S. Representatives are considering a 21st Century Cures Act 2.0, Roche received FDA authorization for a new diagnostic test, and significant legal actions and policy updates are underway in drug pricing and healthcare transparency. Additionally, new Medicaid initiatives and health equity investments aim to improve access to care.
Avalon's Washington, D.C. Policy Update Newsletter 6/3
The healthcare sector is witnessing significant legal and regulatory shifts, including ACLA's lawsuit challenging FDA authority over LDTs and several FDA breakthrough designations for new blood tests. Concurrently, substantial reforms in drug pricing, prior authorization processes, and investments in AI diagnostics and health equity initiatives are driving industry transformation.
Avalon's Washington, D.C. Policy Update Newsletter 5/
This article encapsulates recent shifts in healthcare, spanning regulatory updates, market innovations, and challenges faced by payers and providers. Key highlights include FDA actions on diagnostics, significant funding rounds, executive changes, and ongoing struggles in drug pricing and hospital finances, signaling a dynamic and evolving industry landscape.
Avalon's Monthly Insights
Explore policy and regulatory news, FDA's classification of Lab Developed Tests (LDTs) as medical devices, and a sneak peek into the 2024 Lab Trend Report. Discover how the AvalonSelect Genetic Network simplifies test management, overcoming challenges in quality control and cost control in the expanding genetic testing market. Plus, the importance of improving price transparency in labs and beyond.
Article: Avalon's Washington D.C. Policy Update 5/5
"In today's healthcare realm, regulatory shifts like the FDA's ruling on Lab Developed Tests (LDTs) prompt industry adaptation, while innovations in diagnostics and AI-driven solutions redefine standards. Simultaneously, initiatives addressing transparency, competition, and equity, such as the FTC's ban on noncompete agreements and HHS's Health Care at Home Initiative, drive transformative change across payers, providers, and Medicaid."
Article: Avalon's Washington D.C. Policy Update 4/21
Avalon's Policy Update covers key areas such as Government Lab Policy Changes, Lab Testing News, and Payers, Providers, and Value-Based Care, providing insights into new regulations, advancements in lab testing, and the impact of value-based care on healthcare delivery.
Avalon's Washington, D.C. Policy Update Newsletter 03/2
Join Maverick Health Policy's Q1 2024 Update webinar on April 16th for insights into key industry themes like AI and price transparency, along with a spotlight on the aftermath of the Change Healthcare cyberattack and significant developments in lab issues, payer-provider dynamics, and value-based care initiatives. Register now to stay informed.